SCHEDULE: JPMorgan Chase Discloses Stake in uniQure N.V.

JPMorgan Chase & Co. has updated its Schedule 13G filing to report beneficial ownership of 8.5% of uniQure N.V.'s ordinary shares as of September 30, 2026.

Summary

• JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of uniQure N.V. ordinary shares.
• As of September 30, 2026, JPMorgan Chase & Co. beneficially owned 5,951,794 shares, representing 8.5% of the class.
• This ownership includes sole voting power over 5,654,307 shares and sole dispositive power over 5,943,150 shares.
• The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• JPMorgan Chase & Co. is a significant institutional investor, and its continued or new stake can be seen as a vote of confidence in uniQure N.V.'s long-term prospects.
• The filing clarifies that the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist stance.

Negatives

• The filing does not provide any new operational or financial performance data for uniQure N.V., making it difficult to assess the company's current health.
• The disclosure is a routine regulatory filing and does not inherently signal positive or negative news about uniQure N.V.'s business operations.

Risks

• As a Schedule 13G filing, it indicates a passive investment. However, any change in this passive status could represent a future risk or strategic shift.
• The filing does not detail the specific reasons for the acquisition or disposition of shares, leaving potential strategic intentions unclear.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding uniQure N.V.'s future performance. It is a disclosure of ownership status.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large institutional investors like JPMorgan Chase when they cross certain ownership thresholds. This filing indicates JPMorgan's significant position in the gene therapy sector, where uniQure N.V. operates.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional holding, which may influence market perception and trading activity.
• uniQure N.V. Management: The filing is a standard disclosure and does not directly impact management's operational responsibilities but confirms institutional interest.

Next Steps

• JPMorgan Chase & Co. will continue to monitor its beneficial ownership and file amendments to Schedule 13G as required by SEC regulations.
• uniQure N.V. will continue its operations and report its financial and operational results in subsequent filings.

Key Dates

Keywords

JPMorgan Chase, uniQure N.V., Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investor, Investment Management